Prostate cancer immunotherapy

Xem 1-5 trên 5 kết quả Prostate cancer immunotherapy
  • For decades we have been learning about the interplay between tumors and the immune system. Our knowledge seemed somewhat incomplete and indirect, like listening to the ocean waves through a shell. Only recently, cancer immunotherapy has started to become a reality, with Provenge (Dendreon Corporation, WA), an autologous antigen-presenting cell preparation, earning the approval of United States Food and Drug Administration (FDA) for the treatment of advanced prostate cancer in 2010.

    pdf228p wawawawawa 27-07-2012 42 16   Download

  • Immune system is composed of innate and adaptive responses and plays critical roles in cancer development and destruction. A century ago, Paul Ehrlich postulated that cancer would be quite common in long-lived organisms if not for the protective effects of immunity. About 50 years later, Burnet and Thomas proposed the concept of cancer immunosurveillance based on the experimental evidence of immune recognition of tumor antigens expressed on tumor cells (Dunn et al. 2004 ) . In 1971, the US Congress created a National Cancer Act – a War on Cancer.

    pdf489p hotmoingay 04-01-2013 24 8   Download

  • Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

    pdf11p dauphong3 03-01-2012 24 2   Download

  • The type of cancer that develops in the cortex of the adrenal gland is called adrenal cortical carcinoma. It is also known as adrenocortical cancer (or carcinoma) or just adrenal cancer. In this document, the term adrenal cancer is used to mean cancer that starts in the adrenal cortex. Adrenal cancer most often is discovered for 1 of 2 reasons. The first is that it produces hormones that cause body changes such as weight gain and fluid retention, early puberty in children, or excess facial or body hair growth in women. The second reason an adrenal cancer may be...

    pdf0p khongmuonnghe 07-01-2013 11 1   Download

  • More recently the results of the Prostate Cancer Prevention Trial (PCPT) (Thompson et al. 2003) demonstrated that there is no PSA threshold below which one can confidently exclude a diagnosis of prostate cancer. The PCPT trial protocol required “normal” men with very low levels of PSA to be biopsied at the end of the trial and it was observed that 39.2% of men with a PSA 2.1-3.0 ng/mL, 27.7% of men with a PSA 1.1-2.0 ng/mL, and 16.3% of men with a PSA

    pdf670p ti_du_hoang 10-08-2012 25 4   Download

Đồng bộ tài khoản